Listen to the podcast by Dr Haddad at www.jco.org/podcasts Author affiliations appear at the end of this article. Published online ahead of print at www.jco.org on October 20, 2014. Support information appears at the end of this article. The funding organizations had no role in the design or conduct of the study; the collection, management, analysis, or inter-pretation of the data; or the preparation, review, or approval of the manuscript. The content of this article is solely the responsi-bility of the authors and does not necessar-ily reflect the official views of the National Institutes of Health or the funding entities of the individual centers participating in this study. Authors ’ disclosures of potential conflicts of interest are fou...
Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathog...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
SummaryObjectivesBRAF pV600E mutation is the most common oncogenic event and the most specific mutat...
Background: The BRAF mutation has been shown to be associated with aggressive clinicopathologic char...
Copyright © 2015 Li-Bo Yang et al. This is an open access article distributed under the Creative Com...
PURPOSE: To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillary...
Importance: BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PT...
PURPOSE: To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillar...
Context: Because very few studies have examined the correlation between BRAF mutations and clinicopa...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
clinicopathological parameters i often present with larger tumor size and at a younger age Human Pat...
Background/Aims: The function of BRAF V600E as a prognostic biomarker continues controversial by rea...
In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most...
ABSTRACT Objectives: We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecu...
Introduction: Somatic B-type Raf kinase (BRAF) V600E mutation in exon 15 was frequently found in hi...
Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathog...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
SummaryObjectivesBRAF pV600E mutation is the most common oncogenic event and the most specific mutat...
Background: The BRAF mutation has been shown to be associated with aggressive clinicopathologic char...
Copyright © 2015 Li-Bo Yang et al. This is an open access article distributed under the Creative Com...
PURPOSE: To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillary...
Importance: BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PT...
PURPOSE: To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillar...
Context: Because very few studies have examined the correlation between BRAF mutations and clinicopa...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
clinicopathological parameters i often present with larger tumor size and at a younger age Human Pat...
Background/Aims: The function of BRAF V600E as a prognostic biomarker continues controversial by rea...
In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most...
ABSTRACT Objectives: We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecu...
Introduction: Somatic B-type Raf kinase (BRAF) V600E mutation in exon 15 was frequently found in hi...
Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathog...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
SummaryObjectivesBRAF pV600E mutation is the most common oncogenic event and the most specific mutat...